目的:本研究旨在探讨代谢综合征(MetS)对因单侧乳腺癌相关淋巴水肿(BCRL)而接受复杂减充血治疗(CDT)的患者肢体体积和生活质量(QoL)的影响。
方法:40例单侧BCRL女性患者,其中20人患有MetS(MetS组),20人没有MetS(对照组),包括在研究中。参与者每周5天接受CDT,持续3周。使用卷尺测量参与者的肢体体积(多余体积百分比(PEV)和多余体积减少百分比(PREV)。并在治疗前后使用淋巴水肿生活质量问卷(LYMQoL)评估其QoL。
结果:治疗后,患者的PEV和PREV值以及LYMQoL-症状评分改善(p<0.05);然而,LYMQoL-函数,外观/身体形象,情绪/情绪,MetS组的总体QoL评分没有变化(p>0.05)。在对照组中,PEV和PREV值以及LYMQoL外观/身体图像,情绪/情绪,总体QoL得分提高(p<0.05),但LYMQoL症状和LYMQoL功能评分没有变化(p>0.05)。与MetS组相比,对照组的治疗后PEV和PREV值增加更大(p<0.001)。
结论:该研究表明,CDT是有或没有MetS的BCRL的有效治疗方法;然而,没有MetS的BCRL病例的改善大于有MetS的BCRL病例。因此,发生BCRL的患者在治疗淋巴水肿时应考虑到MetS的存在.
背景:ClinicalTrials.gov,标识符:NCT05426993。注册2022-06-16。https://clinicaltrials.gov/search?cond=NCT05426993.
OBJECTIVE: This study aimed to investigate the effect of the presence of metabolic syndrome (MetS) on the limb volume and quality of life (QoL) of patients who underwent complex decongestive therapy (CDT) due to unilateral breast cancer-related lymphedema (BCRL).
METHODS: Forty female patients with unilateral BCRL, of whom 20 had MetS (MetS group) and 20 did not have MetS (control group), were included in the study. The participants received CDT 5 days a week for 3 weeks. The participants\' limb volume (percentage of excess volume (PEV) and percentage reduction of excess volume (PREV) was determined using a tape measure, and their QoL was assessed using the Lymphedema Quality of Life questionnaire (LYMQoL) before and after treatment.
RESULTS: After the treatment, the PEV and PREV values and LYMQoL-symptoms scores of the patients improved (p < 0.05); however, the LYMQoL-function, appearance/body image, mood/emotions, and overall QoL scores did not change in the MetS group (p > 0.05). In the control group, the PEV and PREV values and the LYMQoL-appearance/body image, mood/emotions, and overall QoL scores improved (p < 0.05), but the LYMQoL-symptoms and LYMQoL-function scores did not change (p > 0.05). There was a greater increase in the post-treatment PEV and PREV values of the control group compared to the MetS group (p < 0.001).
CONCLUSIONS: The study yielded that CDT was an effective treatment in BCRL with and without MetS; however, the improvement was greater in BCRL cases without MetS than in those with MetS. Therefore, the presence of MetS should be taken into account in the treatment of lymphedema in patients who develop BCRL.
BACKGROUND: ClinicalTrials.gov, identifier: NCT05426993. Registered 2022-06-16. https://clinicaltrials.gov/search?cond=NCT05426993.